One Month Follow-up of Haemostatic Variables in Patients Undergoing Aortocoronary Bypass Surgery

Summary It is already known that activation of the coagulation and fibrinolytic system occurs in patients undergoing cardiopulmonary bypass (CPB). We have thus studied twenty patients (10 treated with aprotinin during CPB and 10 untreated) both during the intraoperative period and during thirty days follow up. In untreated patients D-dimer levels increased 4-fold during CPB and the levels were above baseline for the whole follow up (p<0.0001). D-dimer levels were reduced in aprotinin treated patients in comparison to untreated patients (p = 0.0172); levels then gradually increased to the values of the untreated patients over the following 24 h later and remained higher during the thirty day follow up. The behavior of haemostatic variables in the 24 h after CPB did not vary between untreated and aprotinin treated patients. In particular, five minutes after protamine sulphate administration, levels of F1 + 2 and TAT rose significantly (p = 0.0054, p = 0.0022 respectively), whereas fibrinogen significantly decreased (p<0.0001) and PAI-1 antigen levels were reduced. Two days after CPB the concentrations of F1 + 2 and TAT lowered, whereas fibrinogen and PAI-1 antigen levels increased. On the 5th, 8th and 30th days after CPB, F1 + 2 and TAT levels remained higher than those reported at baseline in both groups of patients, whereas fibrinogen levels increased over basal levels in aprotinin treated patients only. Thus, in addition to the activation of the coagulation and fibrinolytic system occurring during the intraoperative period, in patients undergoing CPB, there are alterations of haemostatic variables up to thirty days from surgery.

[1]  P. Mannucci,et al.  Poor Comparability of Prothrombin Fragment 1 + 2 Values Measured by Two Commercial ELISA Methods: Influence of Different Anticoagulants and Standards , 1994, Thrombosis and Haemostasis.

[2]  D. Nilsen,et al.  Lipopolysaccharide Induced Monocyte Thromboplastin Synthesis and Coagulation Responses in Patients Undergoing Coronary Bypass Surgery after Preoperative Supplementation with n-3 Fatty Acids , 1993, Thrombosis and Haemostasis.

[3]  H. Philippou,et al.  Thrombogenic mechanisms in the human: fresh insights obtained by immunodiagnostic studies of coagulation markers. , 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[4]  A. Michelson,et al.  Aprotinin reduces cardiopulmonary bypass‐induced blood loss and inhibits fibrinolysis without influencing platelets , 1993, British journal of haematology.

[5]  S. Brister,et al.  Thrombin Generation during Cardiac Surgery: Is Heparin the Ideal Anticoagulant? , 1993, Thrombosis and Haemostasis.

[6]  S. Downing,et al.  Release of vasoactive substances during cardiopulmonary bypass. , 1992, The Annals of thoracic surgery.

[7]  B. Hunt,et al.  Aprotinin and Heparin Monitoring During Cardiopulmonary Bypass , 1992, Circulation.

[8]  A. Lusky,et al.  Aprotinin Prevents Cardiopulmonary Bypass‐Induced Platelet Dysfunction: A Scanning Electron Microscope Study , 1992, Circulation.

[9]  H. Teufelsbauer,et al.  Early Activation of Hemostasis during Cardiopulmonary Bypass: Evidence for Thrombin Mediated Hyperfibrinolysis , 1992, Thrombosis and Haemostasis.

[10]  J. Soria,et al.  Hemostasis in Patients Undergoing Extracorporeal Circulation: The Effect of Aprotinin (Trasylol) , 1991, Thrombosis and Haemostasis.

[11]  H. Teufelsbauer,et al.  Effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass operation. , 1991, The Journal of thoracic and cardiovascular surgery.

[12]  J. Buring,et al.  Antiplatelet therapy to prevent coronary artery bypass graft occlusion. , 1990, Circulation.

[13]  J. Jespersen,et al.  Enhanced Effective Fibrinolysis following the Neutralization of Heparin in Open Heart Surgery Increases the Risk of Post-Surgical Bleeding , 1990, Thrombosis and Haemostasis.

[14]  F. Ofosu,et al.  A comparative evaluation of assays for markers of activated coagulation and/or fibrinolysis: thrombin–antithrombin complex, D‐dimer and fibrinogen/fibrin fragment E antigen , 1990, British journal of haematology.

[15]  H. Kwaan,et al.  Increased fibrinolytic activity in patients undergoing cardiopulmonary bypass operation , 1986, American journal of hematology.

[16]  A. S. Douglas,et al.  Studies on the Anticoagulant Action of Aprotinin (“Trasylol”) , 1970, Thrombosis and Haemostasis.

[17]  D. Royston Coagulation in cardiac surgery. , 1996, Advances in cardiac surgery.

[18]  J. Levy,et al.  Increased anticoagulation during cardiopulmonary bypass by aprotinin. , 1991, The Journal of thoracic and cardiovascular surgery.

[19]  J. Chesebro,et al.  Evaluation of antiplatelet agents in the prevention of aorto-coronary bypass occlusion. , 1986, European heart journal.